NORTH CHICAGO, IL, USA I 18, 2024 I AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® ...

The ASIST study will assess the safety and efficacy of BXQ-350 plus SOC, modified FOLFOX7 (mFOLFOX7) and bevacizumab, in patients with newly diagnosed mCRC. The study is also evaluating whether the ...

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on November 13. Debanjana ...

A preliminary study of an artificial intelligence-powered program found that it could detect if a person had high blood ...

There was no treatment effect of durvalumab across all subgroups ... creatinine clearance <60 mL/min, hearing impairment, ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sparsentan (Filspari) to treat ...

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, ...

Carson City emergency crews responded Monday morning to a vehicle crash Monday morning at the Fifth Street Bridge.

Friends to All is dedicated to bringing joy, cheer and friendship to seniors in our community during the holiday season.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), a commercial-stage Pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be ...

Clene (NASDAQ:CLNN – Free Report) had its price target cut by Canaccord Genuity Group from $86.00 to $83.00 in a research report released on Thursday morning,Benzinga reports. They currently have a ...

completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial ...